Dengue fever secondary prevention

Ebola Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Ebola from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Algorithm for the Evaluation of the Returned Traveler
Emergency Department Evaluation
Case Definition
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Hospital Preparedness
Checklists
Air Medical Transport
Monitoring and Movement Following Exposure
Primary Prevention
Future or Investigational Therapies
Postmortem Care
Postmortem Care
Case Studies
Case #1
Dengue fever secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dengue fever secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dengue fever secondary prevention
CDC on Dengue fever secondary prevention
Dengue fever secondary prevention in the news
Blogs on Dengue fever secondary prevention
Directions to Hospitals Treating ebola
Risk calculators and risk factors for Dengue fever secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2.